The Neuroplasticity Window: Why Timing Matters in Ketamine Treatment

If you have ever wondered why one treatment can start to shift how you feel within a day or two, while another takes six weeks to do much of anything, the answer often comes down to biology and timing. Ketamine and its cousin esketamine work differently from the antidepressants most people have tried, and part of what makes them different is a short stretch of time after a dose when the brain becomes unusually open to change. Understanding that stretch, sometimes called the neuroplasticity window ketamine researchers study, helps explain why the approach to this kind of treatment looks so different from taking a daily pill.

What the window actually is

Neuroplasticity is the ordinary word for your brain's ability to form and strengthen connections. It is happening all the time, quietly, as you learn a name or a new route to work. What ketamine appears to do is briefly turn up that capacity. Rather than acting mainly on serotonin the way older antidepressants do, ketamine and esketamine act on a different messaging system built around a chemical called glutamate. The effects show up fast, sometimes within hours, and researchers have mapped a roughly 24 to 72 hour period afterward when the brain seems especially primed to build new connections (Zanos and Gould, 2018, Molecular Psychiatry).

Think of it less like a switch that stays flipped and more like a door that opens for a day or two and then eases closed again. What you do while that door is open matters. That is the practical heart of why timing shapes the whole approach.

Why timing changes the approach

Because the window is short and repeats with each dose, treatment is usually structured as a series of visits spaced deliberately rather than a single event. The idea is to return while the brain is still responsive and to pair each dose with the kind of rest, support, and healthy input that gives new connections something worth reinforcing. It is one reason a well-run program measures how you are doing at every visit. A PHQ-9, the short depression questionnaire used at Brain Recovery Centers each time you come in, turns a vague sense of "a little better" into something you can actually track across the weeks.

• The effect is measured in hours, not weeks, so the rhythm of care is different from a daily pill.
• The window recurs with each dose, which is why visits are spaced on purpose.
• What happens between and around doses (sleep, support, follow-up) is part of the treatment, not an afterthought.
• Regular measurement lets your care team adjust rather than guess.

Why standard care sometimes misses the mark

Here is where the story gets more personal for some people. If you took a hard hit years ago, on a field, in a car, off a ladder, in a fight, and you have carried a low, stubborn depression since, you may have tried an antidepressant or two and found they did not move the needle much. That is not a failure of effort, and it may not even be a failure of the medication for what it was designed to do. A meta-analysis of antidepressants started after a head impact found no significant difference from placebo (Foreman et al., 2019, J Head Trauma Rehabil). If a depression is running partly on that glutamate system rather than the serotonin one, a serotonin-focused pill has less to grab onto.

The connection between an old head injury and later mood is more established than many people realize. People who have gotten their bell rung are more than three times as likely to have depression, and that elevated risk can persist for years afterward (Beaton et al., 2020, Frontiers in Neurology). The effects are not only about mood, either. Sleep disorders show up in roughly 30 to 70 percent of people with a head-injury history, and about 1 in 6 develop a hormone deficiency after a hit. When sleep and hormones are quietly off, the depression sitting on top of them is harder to shift, and it is easy for a standard evaluation to miss the layer underneath.

An old hit does not mean you need any particular treatment. It is a risk factor worth understanding, not a diagnosis, and understanding it is the first step toward getting the right help.

Where a neurology lens comes in

This is why having neurology on staff matters as a diagnostic tool. It is not a promise of any outcome, and it is important to be plain about that. Spravato (esketamine) is FDA-approved for treatment-resistant depression, not for concussion or any head injury. What a neurology-informed evaluation offers is a wider lens: a chance to ask whether the depression standard care could not reach might be running on a different system, and whether sleep, hormones, or an old injury history are part of the picture. A history of a head hit is a reason to look more carefully, never a green light for a specific medication on its own.

If any of this is landing close to home, one more note belongs here. Research has linked a concussion history with elevated odds of death by suicide (Erlangsen et al., 2018, JAMA). That is not meant to frighten you. It is meant to say that this kind of depression is real, it is worth taking seriously, and help exists. If you are in crisis or thinking about harming yourself, you can call or text 988 in the United States at any hour to reach a trained, supportive person.

What this means for you

The takeaway is not that a short biological window is a magic key. It is that timing, structure, and honest measurement are what let a treatment like this work the way it is meant to, and that the reason standard care sometimes falls short may have a clear, understandable cause. If you have a stubborn depression that has not responded to the usual approaches, and especially if there is an old head injury somewhere in your story, a proper evaluation from a clinic that has neurology on staff can look at this and help you understand what has been going on. Understanding why the usual path did not work is often the quietest and most useful place to begin.